Dr. Nastoupil on Efficacy With Pembrolizumab and Rituximab in Follicular Lymphoma

Loretta J. Nastoupil, MD
Published: Monday, Aug 28, 2017



Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses efficacy findings of a study investigating the combination of pembrolizumab (Keytruda) and rituximab (Rituxan) in patients with relapsed follicular lymphoma.

Researchers have known that enhancing patients' immune systems for treatment with follicular has been effective, with rituximab being the prime example, Nastoupil explains. The combination strategy could be synergistic in enhancing the patients' immune systems to target their follicular lymphoma cells. This phase II single-center study investigated the combination in relapsed, rituximab-sensitive patients with follicular lymphoma. There were 16 doses of pembrolizumab at 200 mg every 3 weeks, and rituximab was administered at 375 mg/m2 for 4 doses.

Enrollment has been completed, and the efficacy results out of 20 evaluable patients demonstrate an overall response rate of 65%. Fifty percent of these patients achieved a complete response. With 8 months of follow up, these responses seem to be durable, she adds.


Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses efficacy findings of a study investigating the combination of pembrolizumab (Keytruda) and rituximab (Rituxan) in patients with relapsed follicular lymphoma.

Researchers have known that enhancing patients' immune systems for treatment with follicular has been effective, with rituximab being the prime example, Nastoupil explains. The combination strategy could be synergistic in enhancing the patients' immune systems to target their follicular lymphoma cells. This phase II single-center study investigated the combination in relapsed, rituximab-sensitive patients with follicular lymphoma. There were 16 doses of pembrolizumab at 200 mg every 3 weeks, and rituximab was administered at 375 mg/m2 for 4 doses.

Enrollment has been completed, and the efficacy results out of 20 evaluable patients demonstrate an overall response rate of 65%. Fifty percent of these patients achieved a complete response. With 8 months of follow up, these responses seem to be durable, she adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x